NASDAQ:SRPT - Sarepta Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $119.25
Forecasted Upside: 57.45 %
Number of Analysts: 13
Breakdown:
0 Sell Ratings
3 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$75.74 As of 07/5/2022 05:00 PM ET

▲ +0.03 (0.04%)

1 month | 3 months | 12 months

Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

^$119.25

▲ +57.45% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $119.25, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 57.45% upside from the last price of $75.74.

Current Consensus is Buy

The current consensus among 13 contributing investment analysts is to buy stock in Sarepta Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
16 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/12/2021

0 strong buy ratings
14 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/12/2021

0 strong buy ratings
15 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

7/11/2021

0 strong buy ratings
13 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/9/2021

0 strong buy ratings
13 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/7/2022

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/7/2022

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/6/2022

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/6/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/24/2022	Cantor Fitzgerald	Lower Price Target	Overweight	$140.00 ➝ $128.00	Low
6/24/2022	Credit Suisse Group	Lower Price Target	Neutral	$95.00 ➝ $90.00	Low
5/24/2022	The Goldman Sachs Group	Lower Price Target	Buy	$181.00 ➝ $155.00	Medium
5/19/2022	Morgan Stanley	Lower Price Target	Equal Weight	$77.00 ➝ $74.00	Low
4/12/2022	Morgan Stanley	Lower Price Target	Equal Weight	$80.00 ➝ $77.00	Low
3/7/2022	Morgan Stanley	Boost Price Target	Equal Weight	$71.00 ➝ $80.00	High
3/2/2022	Barclays	Lower Price Target		$125.00 ➝ $104.00	Medium
3/2/2022	Royal Bank of Canada	Boost Price Target	Outperform	$145.00 ➝ $150.00	High
2/1/2022	Morgan Stanley	Lower Price Target	Equal Weight	$92.00 ➝ $71.00	Medium
1/18/2022	Morgan Stanley	Boost Price Target	Equal Weight	$90.00 ➝ $92.00	Low
1/11/2022	Needham & Company LLC	Reiterated Rating	Buy	$150.00	Medium
1/5/2022	Needham & Company LLC	Lower Price Target	Buy	$157.00 ➝ $150.00	High
12/9/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$125.00	Medium
11/5/2021	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$88.00 ➝ $130.00	Medium
11/4/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$128.00 ➝ $140.00	High
11/4/2021	Royal Bank of Canada	Lower Price Target	Outperform	$148.00 ➝ $145.00	High
11/4/2021	Needham & Company LLC	Lower Price Target	Buy	$166.00 ➝ $157.00	High
10/15/2021	Berenberg Bank	Reiterated Rating	Hold	$90.00	High
10/12/2021	Credit Suisse Group	Boost Price Target	Neutral	$75.00 ➝ $100.00	High
10/12/2021	SVB Leerink	Reiterated Rating	Buy		High
10/12/2021	Needham & Company LLC	Reiterated Rating	Buy		High
10/12/2021	BTIG Research	Boost Price Target	Buy	$110.00 ➝ $125.00	High
10/7/2021	Robert W. Baird	Initiated Coverage	Buy	$110.00	Medium
9/15/2021	Guggenheim	Upgrade	Neutral ➝ Buy		High
8/16/2021	Morgan Stanley	Lower Price Target	Equal Weight	$93.00 ➝ $90.00	High
8/5/2021	Credit Suisse Group	Boost Price Target	Neutral	$72.00 ➝ $75.00	High
8/5/2021	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$92.00 ➝ $87.00	High
7/1/2021	Berenberg Bank	Initiated Coverage	Hold	$85.00	Medium
6/14/2021	BTIG Research	Initiated Coverage	Buy	$110.00	High
5/3/2021	Needham & Company LLC	Initiated Coverage	Buy	$166.00	High
4/19/2021	Morgan Stanley	Lower Price Target	Equal Weight	$95.00 ➝ $93.00	Low
4/16/2021	William Blair	Reiterated Rating	Buy		Low
3/21/2021	SVB Leerink	Reiterated Rating	Buy		Low
3/2/2021	Royal Bank of Canada	Lower Price Target	Outperform	$143.00 ➝ $132.00	High
3/2/2021	Needham & Company LLC	Reiterated Rating	Buy	$166.00	High
3/2/2021	SVB Leerink	Boost Price Target	Outperform	$125.00 ➝ $126.00	High
3/2/2021	Piper Sandler	Lower Price Target	Neutral	$140.00 ➝ $130.00	High
2/26/2021	Mizuho	Boost Price Target	Buy	$158.00 ➝ $160.00	High
1/12/2021	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		High
1/11/2021	UBS Group	Downgrade	Buy ➝ Neutral		High
1/8/2021	Oppenheimer	Reiterated Rating	Hold ➝ Neutral		High
1/8/2021	Credit Suisse Group	Lower Price Target	Neutral	$156.00 ➝ $73.00	N/A
1/8/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Underweight	$96.00	N/A
1/8/2021	Robert W. Baird	Lower Price Target	Outperform	$223.00 ➝ $110.00	N/A
1/8/2021	Cowen	Lower Price Target	Outperform	$213.00 ➝ $114.00	N/A
1/8/2021	Needham & Company LLC	Lower Price Target	Buy	$182.00 ➝ $166.00	N/A
1/8/2021	Barclays	Lower Price Target	Positive ➝ Overweight	$192.00 ➝ $125.00	N/A
1/8/2021	Cantor Fitzgerald	Lower Price Target	Overweight	$217.00 ➝ $128.00	N/A
1/8/2021	Royal Bank of Canada	Lower Price Target	Outperform	$200.00 ➝ $143.00	N/A
1/8/2021	Mizuho	Lower Price Target	Buy	$204.00 ➝ $158.00	N/A
1/8/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$182.00 ➝ $95.00	N/A
1/8/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
1/8/2021	SVB Leerink	Lower Price Target	Outperform	$197.00 ➝ $125.00	N/A
1/4/2021	Piper Sandler	Boost Price Target	Overweight	$200.00 ➝ $240.00	N/A
12/14/2020	Smith Barney Citigroup	Boost Price Target		$190.00 ➝ $215.00	Low
12/14/2020	Credit Suisse Group	Lower Price Target	Neutral	$162.00 ➝ $156.00	Medium
12/8/2020	Mizuho	Boost Price Target	Buy	$192.00 ➝ $204.00	High
11/11/2020	Berenberg Bank	Initiated Coverage	Hold	$140.00	Medium
11/6/2020	Credit Suisse Group	Lower Price Target	Neutral	$167.00 ➝ $162.00	High
11/6/2020	SVB Leerink	Lower Price Target	Outperform	$214.00 ➝ $197.00	High
10/28/2020	UBS Group	Initiated Coverage	Buy	$212.00	Low
10/11/2020	Royal Bank of Canada	Reiterated Rating	Buy		Low
9/15/2020	Citigroup	Boost Price Target	Buy	$177.00 ➝ $190.00	Medium
8/31/2020	HC Wainwright	Lower Price Target	Buy	$260.00 ➝ $221.00	Low
8/24/2020	Raymond James	Initiated Coverage	Outperform	$200.00	High
8/21/2020	Bank of America	Lower Price Target	Buy	$190.00 ➝ $189.00	Medium
8/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$185.00 ➝ $167.00	High
8/10/2020	Morgan Stanley	Boost Price Target	Overweight	$172.00 ➝ $182.00	Low
8/4/2020	Piper Sandler	Lower Price Target	Overweight	$206.00 ➝ $200.00	Low
8/3/2020	Credit Suisse Group	Reiterated Rating	Buy		Low
6/22/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$160.00 ➝ $190.00	Low
6/16/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	Medium
6/10/2020	Bank of America	Reiterated Rating	Buy	$180.00	High
6/8/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	High
6/8/2020	Robert W. Baird	Reiterated Rating	Buy	$192.00	High
5/17/2020	Nomura	Reiterated Rating	Buy	$230.00	High
5/15/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
5/15/2020	Robert W. Baird	Reiterated Rating	Buy	$192.00	High
5/15/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	High
5/7/2020	Needham & Company LLC	Initiated Coverage	Buy	$182.00	High
5/7/2020	Credit Suisse Group	Reiterated Rating	Buy	$185.00	High
5/7/2020	Oppenheimer	Reiterated Rating	Hold		High
5/6/2020	Royal Bank of Canada	Reiterated Rating	Buy	$182.00	Low
4/30/2020	Mizuho	Reiterated Rating	Buy	$183.00	Low
4/15/2020	Morgan Stanley	Lower Price Target	Overweight	$173.00 ➝ $172.00	Low
3/30/2020	Mizuho	Initiated Coverage	Buy	$183.00	High
2/28/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$172.00 ➝ $160.00	High
2/27/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$211.00 ➝ $217.00	High
2/27/2020	JMP Securities	Lower Price Target	Outperform	$280.00 ➝ $217.00	High
2/25/2020	Nomura Securities	Reiterated Rating	Buy	$230.00	High
1/23/2020	SVB Leerink	Reiterated Rating	Buy	$216.00	Low
1/14/2020	Credit Suisse Group	Reiterated Rating	Buy	$185.00	Low
1/14/2020	Cowen	Reiterated Rating	Buy	$213.00	High
1/7/2020	Bank of America	Reiterated Rating	Buy	$187.00	High
12/30/2019	Oppenheimer	Reiterated Rating	Hold		Low
12/26/2019	Citigroup	Reiterated Rating	Buy	$177.00	Low
12/25/2019	Nomura Securities	Reiterated Rating	Buy	$230.00	Low
12/24/2019	The Goldman Sachs Group	Reiterated Rating	Buy	$180.00	Low
12/24/2019	Morgan Stanley	Boost Price Target	Overweight	$160.00 ➝ $173.00	Low
12/24/2019	Credit Suisse Group	Reiterated Rating	Overweight ➝ Outperform	$190.00 ➝ $185.00	Low
12/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$210.00	N/A
12/23/2019	Royal Bank of Canada	Lower Price Target	Outperform	$215.00 ➝ $200.00	Medium
12/20/2019	Robert W. Baird	Boost Price Target	Outperform	$181.00 ➝ $192.00	Low
12/18/2019	Nomura Securities	Reiterated Rating	Buy	$230.00	Low
12/17/2019	Citigroup	Boost Price Target	Buy	$167.00 ➝ $177.00	Low
12/15/2019	Cowen	Initiated Coverage	Buy	$213.00	Medium
12/15/2019	Barclays	Reiterated Rating	Buy	$202.00	Medium
12/13/2019	HC Wainwright	Boost Price Target		$160.00 ➝ $260.00	Low
12/13/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$175.00 ➝ $211.00	High
12/13/2019	SVB Leerink	Reiterated Rating	Outperform	$186.00 ➝ $216.00	Medium
12/13/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$185.00 ➝ $210.00	High
12/13/2019	Credit Suisse Group	Boost Price Target	Outperform	$185.00 ➝ $190.00	High
12/13/2019	Janney Montgomery Scott	Boost Price Target	Buy	$160.00 ➝ $175.00	High
12/13/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$215.00	High
11/18/2019	Citigroup	Lower Price Target	Buy ➝ Positive	$180.00 ➝ $167.00	Low
11/8/2019	Credit Suisse Group	Lower Price Target	Outperform	$201.00 ➝ $185.00	High
11/1/2019	Guggenheim	Initiated Coverage	Buy	$183.00	High
10/11/2019	Morgan Stanley	Lower Price Target	Overweight	$220.00 ➝ $160.00	Low
10/8/2019	Oppenheimer	Reiterated Rating	Hold		Low
9/27/2019	Piper Jaffray Companies	Set Price Target	Buy	$185.00	Low
9/27/2019	Citigroup	Lower Price Target	Buy	$185.00 ➝ $180.00	Medium
9/24/2019	Royal Bank of Canada	Set Price Target	Buy	$204.00	High
9/13/2019	HC Wainwright	Set Price Target	Buy	$160.00	Low
8/21/2019	Needham & Company LLC	Lower Price Target	Buy	$196.00 ➝ $170.00	Low
8/20/2019	Royal Bank of Canada	Lower Price Target	Outperform	$204.00	Low
8/20/2019	Cantor Fitzgerald	Lower Price Target	Overweight	$231.00 ➝ $175.00	Low
8/20/2019	Robert W. Baird	Lower Price Target	Outperform	$202.00 ➝ $181.00	High
8/20/2019	Bank of America	Lower Price Target	Buy	$200.00 ➝ $189.00	High
8/20/2019	Credit Suisse Group	Lower Price Target	Outperform	$207.00 ➝ $201.00	High
8/20/2019	Janney Montgomery Scott	Lower Price Target	Buy	$200.00 ➝ $175.00	High
8/20/2019	HC Wainwright	Reiterated Rating	Buy	$160.00 ➝ $267.00	High
8/20/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$208.00 ➝ $185.00	High
8/9/2019	William Blair	Reiterated Rating	Buy		Low
8/8/2019	Evercore ISI	Reiterated Rating	Buy	$200.00	High
7/9/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$165.00 ➝ $220.00	Medium
7/1/2019	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$188.00 ➝ $220.00	Low
6/17/2019	HC Wainwright	Set Price Target	Buy	$267.00	Low
5/16/2019	Citigroup	Lower Price Target	Buy	$201.00 ➝ $190.00	Medium
5/14/2019	Morgan Stanley	Lower Price Target	Overweight	$169.00 ➝ $165.00	Medium
5/9/2019	Royal Bank of Canada	Lower Price Target	Outperform	$191.00 ➝ $188.00	High
4/17/2019	BTIG Research	Set Price Target	Buy	$190.00	High
4/11/2019	Evercore ISI	Initiated Coverage	Outperform	$175.00	High
3/31/2019	Cowen	Reiterated Rating	Buy	$213.00	Low
3/28/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$200.00 ➝ $208.00	Low
3/12/2019	BMO Capital Markets	Initiated Coverage	Outperform		Low
3/11/2019	Credit Suisse Group	Reiterated Rating	Outperform ➝ Outperform	$189.00 ➝ $207.00	Low
3/5/2019	SVB Leerink	Reiterated Rating	Outperform		Low
3/4/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$161.00 ➝ $169.00	Low
3/1/2019	Citigroup	Boost Price Target	Buy ➝ Buy	$188.00 ➝ $201.00	Low
2/28/2019	Nomura Securities	Boost Price Target	Buy ➝ Buy	$205.00 ➝ $230.00	Low
2/28/2019	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$217.00 ➝ $231.00	High
2/27/2019	JMP Securities	Reiterated Rating	Buy	$270.00	High
2/22/2019	Cantor Fitzgerald	Reiterated Rating	Buy		High
2/5/2019	BTIG Research	Set Price Target	Buy	$190.00	Low
1/30/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$168.00 ➝ $200.00	High
1/17/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$164.00	Low
1/8/2019	Janney Montgomery Scott	Set Price Target	Buy	$200.00	Medium
1/4/2019	HC Wainwright	Set Price Target	Buy	$267.00	High
12/28/2018	BTIG Research	Set Price Target	Buy	$190.00	Medium
12/10/2018	HC Wainwright	Set Price Target	Buy	$267.00	Low
11/26/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$217.00	High
11/6/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$174.00 ➝ $188.00	Medium
10/26/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$189.00 ➝ $168.00	Low
10/12/2018	Sanford C. Bernstein	Initiated Coverage	Outperform	$170.00	High
10/4/2018	Credit Suisse Group	Boost Price Target		$178.00 ➝ $189.00	High
10/4/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$189.00	High
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$217.00	High
9/26/2018	Royal Bank of Canada	Reiterated Rating	Outperform	$187.00 ➝ $200.00	Medium
9/24/2018	BTIG Research	Set Price Target	Buy	$190.00	Low
9/24/2018	Needham & Company LLC	Lower Price Target	Buy	$196.00	Low
9/21/2018	HC Wainwright	Reiterated Rating	Buy	$267.00	High
9/14/2018	Bank of America	Initiated Coverage	Buy ➝ Buy	$199.00	Low
9/6/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$178.00	Medium
9/4/2018	HC Wainwright	Set Price Target	Buy	$267.00	High
8/14/2018	Citigroup	Initiated Coverage	Buy		Medium
8/9/2018	Cowen	Reiterated Rating	Buy	$178.00	High
8/9/2018	HC Wainwright	Set Price Target	Buy	$267.00	High
8/1/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$163.00	Low
7/18/2018	HC Wainwright	Set Price Target	Buy	$267.00	Medium
6/25/2018	JMP Securities	Boost Price Target	Outperform	$275.00	Low
6/22/2018	SunTrust Banks	Boost Price Target	Buy	$176.00	High
6/21/2018	Nomura Securities	Boost Price Target	Buy ➝ Buy	$131.00 ➝ $205.00	Medium
6/21/2018	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$120.00 ➝ $202.00	Medium
6/20/2018	WBB Securities	Reiterated Rating	Buy		Low
6/20/2018	Royal Bank of Canada	Boost Price Target	Outperform	$189.00	Medium
6/20/2018	Needham & Company LLC	Boost Price Target	Buy	$109.00 ➝ $204.00	Medium
6/20/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$91.00 ➝ $163.00	High
6/20/2018	Cowen	Reiterated Rating	Outperform	$178.00	High
6/20/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform		High
6/20/2018	Barclays	Reiterated Rating	Overweight	$180.00	High
6/20/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$168.00	High
6/19/2018	William Blair	Reiterated Rating	Buy		High
6/19/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight		High
6/19/2018	HC Wainwright	Boost Price Target	Buy	$96.00 ➝ $267.00	High
6/15/2018	BTIG Research	Initiated Coverage	Buy	$120.00	High
6/11/2018	HC Wainwright	Reiterated Rating	Buy	$96.00	Low
5/18/2018	The Goldman Sachs Group	Boost Price Target	Buy	$84.00 ➝ $127.00	Low
5/15/2018	SVB Leerink	Boost Price Target	Hold ➝ Outperform	$88.00 ➝ $121.00	Low
5/11/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $107.00	Low
5/7/2018	Needham & Company LLC	Boost Price Target	In-Line ➝ Buy	$75.00 ➝ $109.00	Low
5/4/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$87.00 ➝ $91.00	High
5/4/2018	Credit Suisse Group	Set Price Target	Outperform ➝ Buy	$100.00 ➝ $92.00	High
5/4/2018	Nomura Securities	Boost Price Target	Buy	$131.00	High
5/4/2018	Royal Bank of Canada	Boost Price Target	Outperform ➝ Positive	$98.00	High
5/4/2018	JMP Securities	Reiterated Rating	Outperform	$95.00 ➝ $90.00	High
5/4/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$90.00 ➝ $96.00	High
5/4/2018	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
5/4/2018	UBS Group	Downgrade	Outperform ➝ Market Perform		High
4/23/2018	HC Wainwright	Reiterated Rating	Buy	$92.00	High
4/5/2018	Credit Suisse Group	Set Price Target	Buy	$100.00	Medium
3/21/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$64.00 ➝ $87.00	Medium
3/16/2018	SunTrust Banks	Boost Price Target	Buy	$95.00	Medium
3/14/2018	Royal Bank of Canada	Reiterated Rating	Buy	$91.00	Medium
3/14/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$75.00 ➝ $95.00	Low
3/13/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$81.00 ➝ $100.00	Low
3/13/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$79.00 ➝ $92.00	Medium
3/12/2018	Credit Suisse Group	Reiterated Rating	Hold	$81.00	High
3/12/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $92.00	High
3/12/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$83.00 ➝ $76.12	High
3/8/2018	SunTrust Banks	Boost Price Target	Buy	$76.00	Medium
3/6/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $64.00	Low
3/2/2018	Credit Suisse Group	Set Price Target	Buy	$81.00	Low
3/2/2018	Nomura Securities	Boost Price Target	Buy	$96.00	High
3/2/2018	HC Wainwright	Set Price Target	Buy	$75.00	High
3/2/2018	Piper Jaffray Companies	Reiterated Rating	Overweight		High
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Overweight	$63.00 ➝ $75.00	Low
2/12/2018	HC Wainwright	Set Price Target	Buy	$75.00	High
2/5/2018	William Blair	Reiterated Rating	Outperform		High
1/23/2018	Barclays	Reiterated Rating	Hold	$55.00	Low
1/22/2018	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform		High
1/19/2018	SVB Leerink	Reiterated Rating	Outperform	$77.00	Low
1/9/2018	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
1/3/2018	Janney Montgomery Scott	Initiated Coverage	Buy ➝ Buy	$75.00	Medium
1/3/2018	HC Wainwright	Set Price Target	Buy	$75.00	Low
12/27/2017	Oppenheimer	Reiterated Rating	Buy	$76.00	Low
12/27/2017	UBS Group	Reiterated Rating	Outperform	$76.00 ➝ $56.51	Low
12/1/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$75.00	High
10/27/2017	Needham & Company LLC	Reiterated Rating	Buy		N/A
10/26/2017	Barclays	Boost Price Target	Equal Weight	$46.00 ➝ $49.00	N/A
10/26/2017	Piper Jaffray Companies	Reiterated Rating	Overweight		N/A
10/17/2017	Robert W. Baird	Reiterated Rating	Buy	$101.00	N/A
10/16/2017	Oppenheimer	Reiterated Rating	Buy	$76.00	N/A
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$71.00	N/A
10/3/2017	Royal Bank of Canada	Reiterated Rating	Buy	$64.00	Low
10/2/2017	William Blair	Reiterated Rating	Outperform		Low
10/2/2017	Nomura Instinet	Reiterated Rating	Buy	$84.00	Low
10/2/2017	Credit Suisse Group	Reiterated Rating	Outperform	$81.00	Low
10/2/2017	Robert W. Baird	Reiterated Rating	Outperform	$101.00	High
10/2/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$60.00	High
9/30/2017	SVB Leerink	Reiterated Rating	Outperform	$66.00	High
9/25/2017	Oppenheimer	Reiterated Rating	Buy		Low
9/25/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
9/15/2017	Royal Bank of Canada	Initiated Coverage	Positive		Low
9/14/2017	Cowen	Reiterated Rating	Outperform	$69.00	Medium
9/7/2017	SunTrust Banks	Reiterated Rating	Buy	$56.00	High
9/7/2017	William Blair	Reiterated Rating	Outperform		High
9/7/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$50.00 ➝ $55.00	High
9/7/2017	Oppenheimer	Reiterated Rating	Buy	$76.00	Low
9/7/2017	Credit Suisse Group	Boost Price Target	Outperform	$5.65 ➝ $81.00	High
9/6/2017	Barclays	Initiated Coverage	Equal Weight	$46.00	Medium
9/6/2017	Needham & Company LLC	Reiterated Rating	Buy	$75.00	Low
9/6/2017	Robert W. Baird	Reiterated Rating	Outperform	$101.00	Low
9/5/2017	Nomura Securities	Reiterated Rating	Buy	$84.00	Low
7/27/2017	William Blair	Reiterated Rating	Outperform		Low
7/24/2017	Janney Montgomery Scott	Boost Price Target	Buy ➝ Fair Value	$65.00 ➝ $73.00	High
7/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00 ➝ $96.00	Low
7/20/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$31.00 ➝ $33.00	High
7/20/2017	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $64.00	High
7/20/2017	Cowen	Reiterated Rating	Outperform	$62.00 ➝ $69.00	High
7/20/2017	SunTrust Banks	Reiterated Rating	Buy		High
7/20/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$50.00	High
7/18/2017	Credit Suisse Group	Set Price Target	Buy	$64.00	High
7/18/2017	SVB Leerink	Reiterated Rating	Buy	$52.00 ➝ $60.00	Low
7/12/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00	Low

(Data available from 7/6/2017 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

10 very positive mentions
5 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

12/8/2021

6 very positive mentions
9 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

1/7/2022

4 very positive mentions
8 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

2/6/2022

2 very positive mentions
8 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/8/2022

0 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/7/2022

3 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

5/7/2022

3 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/6/2022

1 very positive mentions
12 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

7/6/2022

Current Sentiment

Recent Stories by Sentiment

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $75.74

$73.07

$76.00

50 Day Range

MA: $70.66

$62.69

$77.07

52 Week Range

Now: $75.74

$61.28

$101.24

Volume

1,287,868 shs

Average Volume

721,869 shs

Market Capitalization

$6.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?: The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Barclays PLC, Berenberg Bank, BTIG Research, Cantor Fitzgerald, Credit Suisse Group AG, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for SRPT.
What is the current price target for Sarepta Therapeutics?: 0 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $119.25, suggesting a possible upside of 57.4%.
View the latest price targets for SRPT.
What is the current consensus analyst rating for Sarepta Therapeutics?: Sarepta Therapeutics currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics.
View the latest ratings for SRPT.
What other companies compete with Sarepta Therapeutics?: Other companies that are similar to Sarepta Therapeutics include Royalty Pharma, MERCK Kommanditgesellschaft auf Aktien, Genmab A/S, Takeda Pharmaceutical, Genmab A/S, BeiGene, Horizon Therapeutics Public, Catalent, Alnylam Pharmaceuticals, UCB, Shiseido, BioMarin Pharmaceutical, Ono Pharmaceutical, Viatris and United Therapeutics. Learn More about companies similar to Sarepta Therapeutics.
How do I contact Sarepta Therapeutics' investor relations team?: Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (857) 242-4000 and its investor relations email address is [email protected] The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. Learn More about contacing Sarepta Therapeutics investor relations.

NASDAQ:SRPT - Sarepta Therapeutics Stock Price Target and Predictions

Analyst Price Target for SRPT

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.11 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

What is the current price target for Sarepta Therapeutics?

What is the current consensus analyst rating for Sarepta Therapeutics?

What other companies compete with Sarepta Therapeutics?

How do I contact Sarepta Therapeutics' investor relations team?